Open Access. Powered by Scholars. Published by Universities.®

Pharmacy and Pharmaceutical Sciences Commons™

Open Access. Powered by Scholars. Published by Universities.®

Pharmacoeconomics and Pharmaceutical Economics

Institution
Keyword
Publication Year
Publication
Publication Type
File Type

Articles 121 - 134 of 134

Full-Text Articles in Pharmacy and Pharmaceutical Sciences

Developing A Software For Pharmaceutical Promotional Meeting Planning, Michele S. Brouse Apr 2008

Developing A Software For Pharmaceutical Promotional Meeting Planning, Michele S. Brouse

UNLV Theses, Dissertations, Professional Papers, and Capstones

“How wrong I was!” This admission from John H. Young (Young, 2006, p. 340) relates to his first exposure to pharmaceutical marketing more than 20 years ago. Young states he had been “sent to represent the medical group at a planning meeting of the launch of a new non-steroidal.” He felt competent he could hold his own at the meeting. At the planning meeting, however, as competition, inventories, market segments, inventories, formulation issues, opinion leader development, and public relations campaigns highlighted discussions, Young learned he would out of his depth. He needed to, Young determined, learn about marketing and production …

Go to article

Dohad, Influenza And Economists, Stephen E. Snyder Jan 2007

Dohad, Influenza And Economists, Stephen E. Snyder

stephen e snyder

The Developmental Origin of Disease and Health hypothesizes that the early-life, including pre-natal, shocks to health. affects individuals’ later-life health and mortality. Following a line of research established by Doug Almond (2006), we examine whether the 1918 influenza epidemic is a health shock which is orthogonal to chronic health status. Almond, however, does not present results on mortality rates. Our findings are that 1) cross sectional data does not exist which would allow us to treat the influenza epidemic as a field experiment with state-by-state variation, and that when we use what data exists, controlling for geographic variation in health, …

Go to article

Oy Canada! Trade's Non-Solution To "The Problem" Of U.S. Drug Prices, Daniel Gilman Aug 2006

Oy Canada! Trade's Non-Solution To "The Problem" Of U.S. Drug Prices, Daniel Gilman

Faculty Scholarship

Price disparities—price “differentiation” or “discrimination”—in pharmaceuticals markets have, in recent years, been the subject of much discussion. Price sensitivity should come as no surprise: Medicines play an increasingly important role in healthcare, while pharmaceuticals prices continue to rise. When prices vary greatly within markets or between neighboring markets, the pressure towards arbitrage is clear. This paper considers the question whether the re-importation of medicines from Canada or the EU is well advised and argues that it is not. First, we might reasonably question the extent to which we wish, as a matter of policy, to manage pharmaceuticals pricing; among other …

Go to article

Day Of Dialogue On Public Sector Pricing Of Pharmaceutical Products, Population Council Jan 2006

Day Of Dialogue On Public Sector Pricing Of Pharmaceutical Products, Population Council

Formulation/Product Development

For decades, patients, doctors, ethicists, and other interested parties have debated the economics of the pharmaceutical industry. What is the best way to get medications and related products to the people who need them, regardless of their ability to pay? Can prices be lowered without jeopardizing basic research for new drugs? Are pharmaceutical company pricing practices monopolistic? What are the legal and ethical obligations related to drugs developed—partially or fully—with public funds? The Population Council convened a daylong meeting of academics, scientists, representatives from the nonprofit sector, the pharmaceutical industry, foundations, and government donor agencies, and practicing lawyers and doctors. …

Go to article

The Effects Of Price Regulation On Pharmaceutical R&D And Innovation, Heather M. O'Neill, Lena Clarissa Crain Jun 2005

The Effects Of Price Regulation On Pharmaceutical R&D And Innovation, Heather M. O'Neill, Lena Clarissa Crain

Business and Economics Faculty Publications

As rising health care expenditures focus government attention on slowing the growth, the pharmaceutical industry comes under increasing pressure to curb prices of ethical drugs. Pharmaceutical price regulations have been implemented in many countries to control pharmaceutical expenditures. Yet, creating innovative drugs requires enormous R&D costs, which in turn require adequate expected economic returns. Since price controls reduce profits and expected returns, as countries invoke stricter price regulations, firms will either move their R&D process into less regulated markets or move out of innovative R&D. This paper assesses the impact of drug price regulations in Japan compared to market-priced drugs …

Go to article

Entrepreneurial Orientation As A Basis For Classification Within A Service Industry: The Case Of Retail Pharmacy Industry, Thanigavelan Jambulingam, Ravi Kathuria, William R. Doucette Nov 2004

Entrepreneurial Orientation As A Basis For Classification Within A Service Industry: The Case Of Retail Pharmacy Industry, Thanigavelan Jambulingam, Ravi Kathuria, William R. Doucette

Business Faculty Articles and Research

To date, service classification research has primarily taken a macro view, creating service typologies or taxonomies by using dimensions such as customer contact or degree of labor intensity. Such classification schemes, though helpful in deciphering critical management issues and positioning strategies between service industries, tend to treat an entire industry, such as airlines, as a single homogenous entity. However, organizations in the same industry often use intangible resources, such as entrepreneurial orientation processes, to compete with one another. Resource-advantage theory suggests that organizations utilize intangible resources to build long-term strategies and a sustainable competitive advantage leading to superior performance. We …

Go to article

Purchasing Pharmaceuticals (Health, Nutrition And Population (Hnp) Discussion Paper), Ulrika Enemark, Anita Alban, Enrique Seoane-Vazquez Sep 2004

Purchasing Pharmaceuticals (Health, Nutrition And Population (Hnp) Discussion Paper), Ulrika Enemark, Anita Alban, Enrique Seoane-Vazquez

Pharmacy Faculty Books and Book Chapters

This paper discusses the purchasing of pharmaceuticals as a key component of costeffective and equitable healthcare delivery. Pharmaceuticals account for a high, sometimes the dominant share of health expenditures in developing countries, but the desired health outcomes can only be achieved if the adequate medicines reach the right people and are used in the correct way. This requires purchasing arrangements that take into account the information asymmetry between patients and providers, ensure selection of effective, safe and affordable medicines and set economic incentives in a way that encourages rational drug use. The organizational and institutional frameworks define the roles of …

Go to article

Rising Prescription Drug Costs: What Is Involved And What Can Be Done?, James Carroll Jan 2003

Rising Prescription Drug Costs: What Is Involved And What Can Be Done?, James Carroll

Maine Policy Review

The rapid rise of prescription drug costs in the United States has triggered heated debate at the federal and state levels about how to control costs and expand access for those in need. In part, the United States finds itself in this situation because, unlike most countries throughout the world, the federal government thus far has refused to exact federal price restrictions on pharmaceutical products. James Carroll argues that this has left each state in the difficult position of trying to leverage lower costs and expanded access for its citizens. In this article, Carroll provides an overview of these attempts, …

Go to article

What Are The Elements Of A Successful Training Model, As Perceived By Global Corporate Security Heads Working In The Ethical Pharmaceutical Industry?, Kevin P. Schatzle Jan 2003

What Are The Elements Of A Successful Training Model, As Perceived By Global Corporate Security Heads Working In The Ethical Pharmaceutical Industry?, Kevin P. Schatzle

Seton Hall University Dissertations and Theses (ETDs)

.

Go to article

Retirees And Pharmaceutical Costs: Is There Really A Crisis?, Justine Maiello Jul 2002

Retirees And Pharmaceutical Costs: Is There Really A Crisis?, Justine Maiello

Seton Hall University Dissertations and Theses (ETDs)

.

Go to article

Ecuador: Use Commercial Marketing To Increase Sustainability, Frontiers In Reproductive Health Jan 2001

Ecuador: Use Commercial Marketing To Increase Sustainability, Frontiers In Reproductive Health

Reproductive Health

Many nongovernmental organizations sell contraceptives through retail outlets to generate income and expand access to these products. In 1998 Centro Médico de Orientación y Planifación Familiar (CEMOPLAF) employed 25 sales agents in 14 cities throughout Ecuador. These agents sold products, including contraceptive methods and home pregnancy tests, to pharmacies, physicians, other distributors, and nontraditional outlets. Contraceptive sales were CEMOPLAF’s largest source of revenue in 1997. Sales had grown rapidly during 1996–97, but CEMOPLAF managers did not know whether product sales were profitable. With support from the Population Council and Family Health International, CEMOPLAF made a detailed analysis of product sales …

Go to article

Ecuador: Utilice La Mercadotecnia Comercial Para Aumentar La Sustentabilidad, Frontiers In Reproductive Health Jan 2001

Ecuador: Utilice La Mercadotecnia Comercial Para Aumentar La Sustentabilidad, Frontiers In Reproductive Health

Reproductive Health

Muchas organizaciones no gubernamentales venden anticonceptivos a través de detallistas con el fin de generar ingresos y mejorar el acceso a estos productos. En 1998, el Centro Médico de Orientación y Planificación Familiar (CEMOPLAF) empleó a 25 agentes de ventas en 14 ciudades ecuatorianas; estos agentes vendieron productos, incluyendo métodos anticonceptivos y pruebas de embarazo de uso doméstico. Esos productos se vendieron a farmacias, médicos, otros distribuidores y a puntos de venta no tradicionales. La venta de anticonceptivos fue la principal fuente de ingresos de CEMOPLAF en 1997. Las ventas habían crecido rápidamente en el periodo 1996–97, pero los gerentes …

Go to article

Reimbursement For Pharmaceutical Care Services: The California Experience, Jeffery A. Goad, Kathleen Johnson, Michael Rudolph Oct 1999

Reimbursement For Pharmaceutical Care Services: The California Experience, Jeffery A. Goad, Kathleen Johnson, Michael Rudolph

Pharmacy Faculty Articles and Research

"While it is true that pharmacists are changing their practice habits, they are doing so for the betterment of their patients’ drug therapy outcomes and the healthcare system. The pharmacist serves as the vital link between the patient, physician, and healthcare system. By working with patients and physicians, pharmacists have demonstrated in the literature that they can improve patient drug therapy outcomes, thus preventing unnecessary healthcare expenditures (Fincham, 1998). Pharmacists have long been held in highest esteem by patients, being voted the number one trusted professional for 10 consecutive years. The evidence is clear that pharmacists provide a valuable service …

Go to article

Pharmaceuticals And Intellectual Property: Meeting Needs Throughout The World, Thomas G. Field Jr. Jan 1990

Pharmaceuticals And Intellectual Property: Meeting Needs Throughout The World, Thomas G. Field Jr.

Law Faculty Scholarship

To the extent that most people think about patents and other forms of intellectual property at all, they tend to be aware that the owners of such property may have the legal capacity to limit market entry--without fully appreciating the extent to which products or processes that can be easily copied might otherwise be unavailable. Focusing on their function in recouping risk capital, this article will survey the types and functions of intellectual property. Then it will attend to the situation in developing countries, particularly the role of intellectual property in meeting their needs for medical products.

Go to article

First Prev